DOCSLIB.ORG

Smu1 and RED Play an Important Role for the Activation of Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Smu1 and RED Play an Important Role for the Activation of Human Smu1 and RED play an important role for the activation of human spliceosomes Dissertation for the award of the degree „Doctor rerum naturalium“ of the Georg-August-Universität Göttingen within the doctoral program “Molecular Biology of Cells” of the Georg-August University School of Science (GAUSS) submitted by Sandra Maria Keiper from Berlin Göttingen, 2018 Members of the Examination Board: Prof. Dr. Reinhard Lührmann (1st Referee) Department of Cellular Biochemistry Max Planck Institute for Biophysical Chemistry, Göttingen Prof. Dr. Heike Krebber (2nd Referee) Department of Molecular Genetics Georg-August-Universität Göttingen Prof. Dr. Patrick Cramer Department of Molecular Biology Max Planck Institute for Biophysical Chemistry, Göttingen Prof. Dr. Markus Zweckstetter Department for NMR-based Structural Biology Max Planck Institute for Biophysical Chemistry, Göttingen Prof. Dr. Jörg Großhans Department of Developmental Biochemistry University Medical Center Göttingen Prof. Dr. Ralph Kehlenbach Department of Molecular Biology University Medical Center Göttingen Date of oral examination: September 27th 2018 For Oskar Table of Contents Abstract .................................................................................................................................................................. 1 1. Introduction ........................................................................................................................................................ 4 1.1 Basic structure of pre-mRNAs ...................................................................................................................... 4 1.2 Pre-mRNA splicing mechanism ................................................................................................................... 5 1.3 Trans-splicing ............................................................................................................................................... 6 1.4 snRNPs – the major building blocks of the spliceosome .............................................................................. 7 1.4.1 The small nuclear RNAs ...................................................................................................................... 7 1.4.2 The snRNP-specific proteins ............................................................................................................... 8 1.5 Spliceosome assembly .............................................................................................................................. 10 1.6 Gene architecture and pre-mRNA splicing ................................................................................................. 13 1.6.1 Alternative splicing ............................................................................................................................. 13 1.6.2 Co-transcriptional splicing ................................................................................................................. 15 1.6.3 Exon-definition pathway .................................................................................................................... 16 1.6.4 Spliceosome assembly requires a minimum intron length ................................................................. 18 1.7 Dynamic RNA/RNA interaction network ..................................................................................................... 18 1.8 Dynamic protein composition of the spliceosome ...................................................................................... 20 1.9 Post-translational phosphorylation of proteins during splicing .................................................................... 22 1.10 The structure of the human B complex and the organization of the B-specific proteins ........................... 23 1.11 Aims ......................................................................................................................................................... 27 2. Materials and methods .................................................................................................................................... 29 2.1 Materials .................................................................................................................................................... 29 2.1.1 Chemicals .......................................................................................................................................... 29 2.1.2 Consumables..................................................................................................................................... 31 2.1.3 Chromatographic resins and columns ............................................................................................... 32 2.1.4 Commerical kits and buffers .............................................................................................................. 32 2.1.5 Machines ........................................................................................................................................... 32 2.1.6 Nucleotides ........................................................................................................................................ 34 2.1.7 Radiolabeled nucleotides .................................................................................................................. 34 2.1.8 Oligonucleotides ................................................................................................................................ 34 2.1.9 siRNAs .............................................................................................................................................. 36 2.1.10 Plasmids .......................................................................................................................................... 36 2.1.11 Antibodies ........................................................................................................................................ 37 2.1.12 Proteins, enzyme inhibitors and enzymes and ................................................................................ 38 2.1.13 Bacteria strains ................................................................................................................................ 38 2.1.14 Cell lines .......................................................................................................................................... 38 2.1.15 Commercial media ........................................................................................................................... 39 2.1.16 Buffers, media and solutions ........................................................................................................... 39 2.2 Methods ..................................................................................................................................................... 45 2.2.1 Molecular biology standard methods ................................................................................................. 45 2.2.1.1 PCR amplification ..................................................................................................................... 45 2.2.1.2 Restriction digest of DNA .......................................................................................................... 46 2.2.1.3 Ligation of digested insert and vector ....................................................................................... 46 2.2.1.4 Nucleic acid quantification ......................................................................................................... 47 2.2.1.5 PCI extraction ........................................................................................................................... 47 2.2.1.6 Proteinase K digestion .............................................................................................................. 47 2.2.1.7 Generation of truncated MINX, PM5 and PM5-10 constructs ................................................... 48 2.2.1.8 Generation of MINX-80-cleaved ................................................................................................ 50 2.2.1.9 In vitro transcription ................................................................................................................... 50 2.2.1.10 Denaturing polyacrylamide gel electrophoresis ....................................................................... 51 2.2.1.11 SYBR® Gold Nucleic Acid Gel Staining ................................................................................... 51 2.2.1.12 Agarose gel electrophoresis of nucleic acids .......................................................................... 51 2.2.2 Protein-biochemistry standard methods ............................................................................................ 52 2.2.2.1 Protein quantification ................................................................................................................ 52 2.2.2.2 Denaturing SDS polyacrylamide gel-electrophoresis (SDS-PAGE) .......................................... 52 2.2.2.3 Coomassie staining ................................................................................................................... 53 2.2.2.4 Western blot .............................................................................................................................. 53 2.2.2.5 Northern blot ............................................................................................................................
Load more

Recommended publications
  • Smu1 and RED Are Required for Activation of Spliceosomal B Complexes Assembled on Short Introns
    ARTICLE https://doi.org/10.1038/s41467-019-11293-8 OPEN Smu1 and RED are required for activation of spliceosomal B complexes assembled on short introns Sandra Keiper 1, Panagiotis Papasaikas 2,4,5, Cindy L. Will1, Juan Valcárcel2,3, Cyrille Girard1 & Reinhard Lührmann1 1234567890():,; Human pre-catalytic spliceosomes contain several proteins that associate transiently just prior to spliceosome activation and are absent in yeast, suggesting that this critical step is more complex in higher eukaryotes. We demonstrate via RNAi coupled with RNA-Seq that two of these human-specific proteins, Smu1 and RED, function both as alternative splicing regulators and as general splicing factors and are required predominantly for efficient splicing of short introns. In vitro splicing assays reveal that Smu1 and RED promote spliceosome activation, and are essential for this step when the distance between the pre-mRNA’s5′ splice site (SS) and branch site (BS) is sufficiently short. This Smu1-RED requirement can be bypassed when the 5′ and 3′ regions of short introns are physically separated. Our obser- vations suggest that Smu1 and RED relieve physical constraints arising from a short 5′SS-BS distance, thereby enabling spliceosomes to overcome structural challenges associated with the splicing of short introns. 1 Department of Cellular Biochemistry, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany. 2 Centre de Regulació Genòmica, The Barcelona Institute of Science and Technology and Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain. 3 Institució Catalana de Recerca i Estudis Avançats (ICREA), Pg. Lluís Companys, 08010 Barcelona, Spain. 4Present address: Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse 66, 4058 Basel, Switzerland.
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Essential Genes Shape Cancer Genomes Through Linear Limitation of Homozygous Deletions
    ARTICLE https://doi.org/10.1038/s42003-019-0517-0 OPEN Essential genes shape cancer genomes through linear limitation of homozygous deletions Maroulio Pertesi1,3, Ludvig Ekdahl1,3, Angelica Palm1, Ellinor Johnsson1, Linnea Järvstråt1, Anna-Karin Wihlborg1 & Björn Nilsson1,2 1234567890():,; The landscape of somatic acquired deletions in cancer cells is shaped by positive and negative selection. Recurrent deletions typically target tumor suppressor, leading to positive selection. Simultaneously, loss of a nearby essential gene can lead to negative selection, and introduce latent vulnerabilities specific to cancer cells. Here we show that, under basic assumptions on positive and negative selection, deletion limitation gives rise to a statistical pattern where the frequency of homozygous deletions decreases approximately linearly between the deletion target gene and the nearest essential genes. Using DNA copy number data from 9,744 human cancer specimens, we demonstrate that linear deletion limitation exists and exposes deletion-limiting genes for seven known deletion targets (CDKN2A, RB1, PTEN, MAP2K4, NF1, SMAD4, and LINC00290). Downstream analysis of pooled CRISPR/Cas9 data provide further evidence of essentiality. Our results provide further insight into how the deletion landscape is shaped and identify potentially targetable vulnerabilities. 1 Hematology and Transfusion Medicine Department of Laboratory Medicine, BMC, SE-221 84 Lund, Sweden. 2 Broad Institute, 415 Main Street, Cambridge, MA 02142, USA. 3These authors contributed equally: Maroulio Pertesi, Ludvig Ekdahl. Correspondence and requests for materials should be addressed to B.N. (email: [email protected]) COMMUNICATIONS BIOLOGY | (2019) 2:262 | https://doi.org/10.1038/s42003-019-0517-0 | www.nature.com/commsbio 1 ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0517-0 eletion of chromosomal material is a common feature of we developed a pattern-based method to identify essential genes Dcancer genomes1.
    [Show full text]
  • The Neurodegenerative Diseases ALS and SMA Are Linked at The
    Nucleic Acids Research, 2019 1 doi: 10.1093/nar/gky1093 The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky1093/5162471 by [email protected] on 06 November 2018 Binkai Chi, Jeremy D. O’Connell, Alexander D. Iocolano, Jordan A. Coady, Yong Yu, Jaya Gangopadhyay, Steven P. Gygi and Robin Reed* Department of Cell Biology, Harvard Medical School, 240 Longwood Ave. Boston MA 02115, USA Received July 17, 2018; Revised October 16, 2018; Editorial Decision October 18, 2018; Accepted October 19, 2018 ABSTRACT Fused in Sarcoma (FUS) and TAR DNA Binding Protein (TARDBP) (9–13). FUS is one of the three members of Understanding the molecular pathways disrupted in the structurally related FET (FUS, EWSR1 and TAF15) motor neuron diseases is urgently needed. Here, we family of RNA/DNA binding proteins (14). In addition to employed CRISPR knockout (KO) to investigate the the RNA/DNA binding domains, the FET proteins also functions of four ALS-causative RNA/DNA binding contain low-complexity domains, and these domains are proteins (FUS, EWSR1, TAF15 and MATR3) within the thought to be involved in ALS pathogenesis (5,15). In light RNAP II/U1 snRNP machinery. We found that each of of the discovery that mutations in FUS are ALS-causative, these structurally related proteins has distinct roles several groups carried out studies to determine whether the with FUS KO resulting in loss of U1 snRNP and the other two members of the FET family, TATA-Box Bind- SMN complex, EWSR1 KO causing dissociation of ing Protein Associated Factor 15 (TAF15) and EWS RNA the tRNA ligase complex, and TAF15 KO resulting in Binding Protein 1 (EWSR1), have a role in ALS.
    [Show full text]
  • View and Standard Neuropathological Analysis of Brain Sections from Affected Pedigree Members
    BMC Neurology BioMed Central Research article Open Access Pedigree with frontotemporal lobar degeneration – motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9 Agnes A Luty1,2,3, John BJ Kwok1,2,3, Elizabeth M Thompson4, Peter Blumbergs5, William S Brooks1,2, Clement T Loy1,2,3, Carol Dobson- Stone1,2, Peter K Panegyres6,7, Jane Hecker8, Garth A Nicholson9,10, Glenda M Halliday1,2 and Peter R Schofield*1,2,3 Address: 1Prince of Wales Medical Research Institute, Sydney, NSW, Australia, 2University of New South Wales, Sydney, NSW, Australia, 3Garvan Institute of Medical Research, Sydney, NSW, Australia, 4SA Clinical Genetics Service, Women's and Children's Hospital, Adelaide, SA, Australia, 5Institute of Medical and Veterinary Science, Adelaide, SA, Australia, 6Neurosciences Unit, Department of Health, Perth, WA, Australia, 7Neurodegenerative Disorders Research, Subiaco, WA, Australia, 8College Grove Private Hospital, Adelaide, SA, Australia, 9Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord Hospital, Sydney, NSW, Australia and 10Faculty of Medicine, University of Sydney, Sydney, Australia Email: Agnes A Luty - [email protected]; John BJ Kwok - [email protected]; Elizabeth M Thompson - [email protected]; Peter Blumbergs - [email protected]; William S Brooks - [email protected]; Clement T Loy - [email protected]; Carol Dobson-Stone - [email protected]; Peter K Panegyres - [email protected]; Jane Hecker - [email protected]; Garth A Nicholson - [email protected]; Glenda M Halliday - [email protected]; Peter R Schofield* - [email protected] * Corresponding author Published: 29 August 2008 Received: 20 June 2008 Accepted: 29 August 2008 BMC Neurology 2008, 8:32 doi:10.1186/1471-2377-8-32 This article is available from: http://www.biomedcentral.com/1471-2377/8/32 © 2008 Luty et al; licensee BioMed Central Ltd.
    [Show full text]
  • Clinical Efficacy and Immune Regulation with Peanut Oral
    Clinical efficacy and immune regulation with peanut oral immunotherapy Stacie M. Jones, MD,a Laurent Pons, PhD,b Joseph L. Roberts, MD, PhD,b Amy M. Scurlock, MD,a Tamara T. Perry, MD,a Mike Kulis, PhD,b Wayne G. Shreffler, MD, PhD,c Pamela Steele, CPNP,b Karen A. Henry, RN,a Margaret Adair, MD,b James M. Francis, PhD,d Stephen Durham, MD,d Brian P. Vickery, MD,b Xiaoping Zhong, MD, PhD,b and A. Wesley Burks, MDb Little Rock, Ark, Durham, NC, New York, NY, and London, United Kingdom Background: Oral immunotherapy (OIT) has been thought to noted during OIT resolved spontaneously or with induce clinical desensitization to allergenic foods, but trials antihistamines. By 6 months, titrated skin prick tests and coupling the clinical response and immunologic effects of peanut activation of basophils significantly declined. Peanut-specific OIT have not been reported. IgE decreased by 12 to 18 months, whereas IgG4 increased Objective: The study objective was to investigate the clinical significantly. Serum factors inhibited IgE–peanut complex efficacy and immunologic changes associated with OIT. formation in an IgE-facilitated allergen binding assay. Secretion Methods: Children with peanut allergy underwent an OIT of IL-10, IL-5, IFN-g, and TNF-a from PBMCs increased over protocol including initial day escalation, buildup, and a period of 6 to 12 months. Peanut-specific forkhead box protein maintenance phases, and then oral food challenge. Clinical 3 T cells increased until 12 months and decreased thereafter. In response and immunologic changes were evaluated. addition, T-cell microarrays showed downregulation of genes in Results: Of 29 subjects who completed the protocol, 27 ingested apoptotic pathways.
    [Show full text]
  • Table S1 & S2.Pdf
    Supplementary Table S1: Factors identified in primary screen for inhibitors of poly-(A+) export Gene GO Function(s) Human Homolog Splicing factor, associates with snRNP U5 components, also involved in transcriptional Bx42 PE regulation SNW1 Cap-G CM Condensin subunit, mitotic chromosome condensation NCAPG Cas NT Nuclear protein transport, Importin-α3 export factor CSE1L CG10059/MAGE* U Unknown MAGE; NDNL2 CG11198/ACC1 O Acetyl Co-A carboxylase ACAC CG12236* U Unknown ZNF295 CG14641 PE Splicing factor, spliceosome component RBM22 CG14701 U Unknown ZCLS2; DPH3 CG18591 PE Splicing factor, snRNP component SNRPE CG2063 U Unknown SAP30BP CG2685 U Unknown WBP11 CG2807 PE Splicing factor, snRNP U2 component SF3B1 CG2921* U Unknown C6orf211 CG30376 U Unknown - CG31126 U Unknown BOLA1 CG32267 U Unknown - CG5451* U Unknown SMU1 CG5931 PE Splicing factor, DEAD-box RNA helicase ASCC3L1 CG6694 U Unknown ZC3H3 CG7214 U Unknown - CG7351/dmPCID2 O Immune response, TNF family member protein, phospholipase 2A activity PCID2 CycD CM Cell cycle control, G1 cyclin CCND2 CycE CM Cell cycle control, G1/S transition CCNE1 DebB PE Splicing factor, snRNP component SNRPF emb NT Nuclear protein transport, Importin-β3 import factor XPO1 Fs* O Follistatin, inhibitor of activin, affects growth factor signalling FST Hel25E/UAP56 PE mRNA splicing and export factor, DEAD-box RNA helicase BAT1 Hpr1 PE Component of the TREX complex, couples transcription to mRNA splicing and export THOC1 Karybeta3 NT Nuclear protein transport, Importin-β3 import factor RanBP5 l(1)10Bb U Unknown
    [Show full text]
  • Expression Profiling of WD40 Family Genes Including DDB1- and CUL4
    Mistry et al. BMC Genomics (2020) 21:602 https://doi.org/10.1186/s12864-020-07016-9 RESEARCH ARTICLE Open Access Expression profiling of WD40 family genes including DDB1- and CUL4- associated factor (DCAF) genes in mice and human suggests important regulatory roles in testicular development and spermatogenesis Bhavesh V. Mistry1, Maha Alanazi1, Hanae Fitwi1,2, Olfat Al-Harazi3, Mohamed Rajab1, Abdullah Altorbag1, Falah Almohanna1, Dilek Colak2 and Abdullah M. Assiri1,3,4* Abstract Background: The WD40-repeat containing proteins, including DDB1–CUL4-associated factors (DCAFs), are abundant and conserved proteins that play important roles in different cellular processes including spermatogenesis. DCAFs are subset of WD40 family proteins that contain WDxR motif and have been proposed to function as substrate receptor for Cullin4-RING-based E3 ubiquitin ligase complexes to recruit diverse proteins for ubiquitination, a vital process in spermatogenesis. Large number of WD40 genes has been identified in different species including mouse and human. However, a systematic expression profiling of WD40 genes in different tissues of mouse and human has not been investigated. We hypothesize that large number of WD40 genes may express highly or specifically in the testis, where their expression is uniquely regulated during testis development and spermatogenesis. Therefore, the objective of this study is to mine and characterize expression patterns of WD40 genes in different tissues of mouse and human with particular emphasis on DCAF genes expressions during mouse testicular development. (Continued on next page) * Correspondence: [email protected] 1Department of Comparative Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia 3Biostatistics, Epidemiology and Scientific Computing Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia Full list of author information is available at the end of the article © The Author(s).
    [Show full text]
  • 1 Imipramine Treatment and Resiliency Exhibit Similar
    Imipramine Treatment and Resiliency Exhibit Similar Chromatin Regulation in the Mouse Nucleus Accumbens in Depression Models Wilkinson et al. Supplemental Material 1. Supplemental Methods 2. Supplemental References for Tables 3. Supplemental Tables S1 – S24 SUPPLEMENTAL TABLE S1: Genes Demonstrating Increased Repressive DimethylK9/K27-H3 Methylation in the Social Defeat Model (p<0.001) SUPPLEMENTAL TABLE S2: Genes Demonstrating Decreased Repressive DimethylK9/K27-H3 Methylation in the Social Defeat Model (p<0.001) SUPPLEMENTAL TABLE S3: Genes Demonstrating Increased Repressive DimethylK9/K27-H3 Methylation in the Social Isolation Model (p<0.001) SUPPLEMENTAL TABLE S4: Genes Demonstrating Decreased Repressive DimethylK9/K27-H3 Methylation in the Social Isolation Model (p<0.001) SUPPLEMENTAL TABLE S5: Genes Demonstrating Common Altered Repressive DimethylK9/K27-H3 Methylation in the Social Defeat and Social Isolation Models (p<0.001) SUPPLEMENTAL TABLE S6: Genes Demonstrating Increased Repressive DimethylK9/K27-H3 Methylation in the Social Defeat and Social Isolation Models (p<0.001) SUPPLEMENTAL TABLE S7: Genes Demonstrating Decreased Repressive DimethylK9/K27-H3 Methylation in the Social Defeat and Social Isolation Models (p<0.001) SUPPLEMENTAL TABLE S8: Genes Demonstrating Increased Phospho-CREB Binding in the Social Defeat Model (p<0.001) SUPPLEMENTAL TABLE S9: Genes Demonstrating Decreased Phospho-CREB Binding in the Social Defeat Model (p<0.001) SUPPLEMENTAL TABLE S10: Genes Demonstrating Increased Phospho-CREB Binding in the Social
    [Show full text]
  • Interactome Analyses Revealed That the U1 Snrnp Machinery Overlaps
    www.nature.com/scientificreports OPEN Interactome analyses revealed that the U1 snRNP machinery overlaps extensively with the RNAP II Received: 12 April 2018 Accepted: 24 May 2018 machinery and contains multiple Published: xx xx xxxx ALS/SMA-causative proteins Binkai Chi1, Jeremy D. O’Connell1,2, Tomohiro Yamazaki1, Jaya Gangopadhyay1, Steven P. Gygi1 & Robin Reed1 Mutations in multiple RNA/DNA binding proteins cause Amyotrophic Lateral Sclerosis (ALS). Included among these are the three members of the FET family (FUS, EWSR1 and TAF15) and the structurally similar MATR3. Here, we characterized the interactomes of these four proteins, revealing that they largely have unique interactors, but share in common an association with U1 snRNP. The latter observation led us to analyze the interactome of the U1 snRNP machinery. Surprisingly, this analysis revealed the interactome contains ~220 components, and of these, >200 are shared with the RNA polymerase II (RNAP II) machinery. Among the shared components are multiple ALS and Spinal muscular Atrophy (SMA)-causative proteins and numerous discrete complexes, including the SMN complex, transcription factor complexes, and RNA processing complexes. Together, our data indicate that the RNAP II/U1 snRNP machinery functions in a wide variety of molecular pathways, and these pathways are candidates for playing roles in ALS/SMA pathogenesis. Te neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) has no known treatment, and elucidation of disease mechanisms is urgently needed. Tis problem has been especially daunting, as mutations in greater than 30 genes are ALS-causative, and these genes function in numerous cellular pathways1. Tese include mitophagy, autophagy, cytoskeletal dynamics, vesicle transport, DNA damage repair, RNA dysfunction, apoptosis, and pro- tein aggregation2–6.
    [Show full text]
  • Exclusion of GNE and Three Other Candidate Genes
    Neuromuscular Disorders 13 (2003) 559–567 www.elsevier.com/locate/nmd Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes Giles D.J. Wattsa, M. Thorneb, M.J. Kovachc, A. Pestronkd, Virginia E. Kimonisa,* aDivision of Genetics and Metabolism, Children’s Hospital, Harvard Medical School, 300 Longwood Avenue, Fegan 5, Boston, MA 02115, USA bHHMI at Children’s Hospital Boston, Boston, MA, USA cBiological and Environmental Sciences, University of Tennessee, Chattanooga, TN, USA dDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA Received 6 November 2002; received in revised form 12 February 2003; accepted 21 March 2003 Abstract We have previously reported a new autosomal dominant inclusion body myopathy clinically resembling limb girdle muscular dystrophy, associated with Paget disease of bone in the majority and frontotemporal dementia in a third of individuals. The critical locus for this unique disorder now termed IBMPFD is 9p21.1–p12, spans 5.5 Mb and contains the gene responsible for the recessive quadriceps-sparing inclusion body myopathy (IBM2). Mutation analysis of the GNE gene associated with IBM2 in affected individuals from four IBMPFD families did not identify any mutations, indicating that the two disorders are not allelic. Expression studies indicate that GNE has a tissue-specific splice pattern, with four splice variants. Mutation analysis in three other candidate genes (b-tropomyosin, NDUFB6 and SMU1) did not identify any mutations. q 2003 Elsevier B.V. All rights reserved. Keywords: Inclusion body myopathy; Limb girdle muscular dystrophy; Paget disease of the bone; Frontotemporal dementia; GNE; IBM2 1.
    [Show full text]
  • Modifiers of Beta-Amyloid Metabolism and Deposition in Mouse Models of Alzheimer’S Disease
    MODIFIERS OF BETA-AMYLOID METABOLISM AND DEPOSITION IN MOUSE MODELS OF ALZHEIMER’S DISEASE by STEFANIE SCHRUMP Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Adviser: Bruce Lamb, Ph.D. Department of Genetics CASE WESTERN RESERVE UNIVERSITY August, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Stefanie Elaine Schrump______________________________________ candidate for the Doctor of Philosophy degree *. (signed) Mitch Drumm_______________________________________ (chair of the committee) Bruce Lamb_________________________________________ Anna Mitchell_______________________________________ Gary Landreth_______________________________________ ___________________________________________________ (date) May 9, 2011____________ *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Copyright © 2011 by Stefanie E. Schrump All rights reserved 3 This thesis is dedicated to my children, the greatest accomplishments of my life. 4 TABLE OF CONTENTS Chapter 1: Introduction and Research Aims………………………………….16 Introduction to Alzheimer’s Disease Alzheimer’s Disease Hallmarks Alzheimer’s Disease Epidemiology APP, Abeta and the Amyloid Hypothesis Mouse Models of Alzheimer’s Disease Research Aims Chapter 2: Gene-Environment Interactions Influence Beta-Amyloid Metabolism in Mice…………………………………………………..60 Abstract Introduction Materials and Methods Results Discussion Chapter 3: The Role of
    [Show full text]